Skip to menu Skip to content Skip to footer
Professor Maher Gandhi
Professor

Maher Gandhi

Email: 

Overview

Background

Maher Gandhi received his medical degree in the UK in 1989, and then trained as a haematologist, including a Fellowship in malignant haematology at Princess Margaret Cancer Centre, Toronto. He was awarded a PhD in immunology at Cambridge University under Patrick Sissons. In 2003 he moved to Brisbane, and works as a Senior Staff Specialist (Pre-Eminent Status) in the Haematology / Oncology Department of the Princess Alexandra Hospital. He leads his own laboratory group and has established an international reputation studying immunity and identification of novel biomarkers in lymphoma, with continuous NHMRC funding since 2005. He was Chair of Laboratory Sciences for the Australasian Leukaemia and Lymphoma Group between 2010-2016, won the prestigious Australian Society of Medical Research Clinical Research Award in 2010 and in 2012 took up the inaugural John McCaffrey Cancer Council of Queensland / Office of Health and Medical Research Clinical Research Fellowship. Between 2011-2014 he was privileged to serve as Chair of the Metro South Human Research Ethics Committee. In 2013 he was appointed Professor of Experimental Haematology, University of Queensland, based at the Translational Research Institute, in 2014 became the inaugural Leukaemia Foundation Chair of Blood Cancer Research at the University of Queensland Diamantina Institute, and was appointed Diamantina Cancer Program Head in 2016. In 2018 to current, he moved to Mater Research, where he is Executive Director, as well Director of MRI-UQ.

Availability

Professor Maher Gandhi is:
Available for supervision
Media expert

Qualifications

  • Bachelor of Medicine Surgery, University of Aberdeen
  • Doctor of Philosophy, University of Cambridge

Research interests

  • Lymphoma

  • Immunotherapy

  • Biomarkers

Research impacts

The research of the Blood Cancer Research Laboratory aims to understand the basis of lymphoma; to devise new treatments which are less toxic and more effective; to establish new biomarkers which will help determine the most effective treatment strategies and to monitor response and relapse and understand the development of lymphomas. The group has a strong emphasis on patient material, which it obtains from international and national clinical collaborators. Lymphomas studied include Hodgkin Lymphoma, PTLD, Diffuse Large B-cell Lymphoma, Follicular Lymphoma and virus associated lymphomas. We utilise a broad range of approaches including genomics, molecular and cellular biology techniques and functional immunoassays. Several of our studies are linked with the Australasian Leukaemia and Lymphoma Group.

The Mater Foundation, the Leukaemia Foundation, and the Brisbane Girls Grammar School Kirsten Jack Memorial Fund are thanked for their kind support.

Works

Search Professor Maher Gandhi’s works on UQ eSpace

211 works between 1993 and 2024

121 - 140 of 211 works

2012

Journal Article

EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors

White, Robert E., Raemer, Patrick C., Naresh, Kikkeri N., Meixlsperger, Sonja, Pinaud, Laurie, Rooney, Cliona, Savoldo, Barbara, Coutinho, Rita, Boedoer, Csaba, Gribben, John, Ibrahim, Hazem A., Bower, Mark, Nourse, Jamie P., Gandhi, Maher K., Middeldorp, Jaap, Cader, Fathima Z., Murray, Paul, Muenz, Christian and Allday, Martin J. (2012). EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. Journal of Clinical Investigation, 122 (4), 1487-1502. doi: 10.1172/JCI58092

EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors

2012

Journal Article

Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma

Jones, Kimberley, Nourse, Jamie P., Keane, Colm, Crooks, Pauline, Gottlieb, David, Ritchie, David S., Gill, Devinder and Gandhi, Maher K. (2012). Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. American Journal of Hematology, 87 (3), 258-265. doi: 10.1002/ajh.22252

Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma

2012

Journal Article

High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease

Mutsando, Howard, Fahim, Magid, Gill, Devinder S., Hawley, Carmel M., Johnson, David W., Maher, K. Gandhi, Marlton, Paula V., Mar Fan, Helen G. and Mollee, Peter N. (2012). High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease. American Journal of Blood Research, 2 (1), 66-70.

High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease

2012

Conference Publication

Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma

Camilleri, Emily T., Aya-Bonilla, Carlos A., Brown, Philip J., Banham, Alison, Marlton, Paula, Gandhi, Maher K. and Griffiths, Lyn R. (2012). Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology.

Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma

2012

Journal Article

The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms

Nourse, Jamie P., Lea, Rod, Crooks, Pauline, Wright, Gillian, Tran, Huyen, Catalano, John, Brighton, Tim, Grigg, Andrew, Marlton, Paula and Gandhi, Maher K. (2012). The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. Blood Coagulation and Fibrinolysis, 23 (1), 45-50. doi: 10.1097/MBC.0b013e32834d7ce3

The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms

2012

Book Chapter

Rituximab induced late-onset neutropenia

Keane, Colm, Nourse, Jamie P. and Gandhi, Maher K. (2012). Rituximab induced late-onset neutropenia. Rituximab: Pharmacology, Clinical Uses and Health Effects. (pp. 93-102) Hauppauge, NY United States: Nova Science Publishers.

Rituximab induced late-onset neutropenia

2012

Conference Publication

Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma

Gandhi, Maher K., Vari, Frank, Crooks, Pauline, Keane, Colm, Nourse, Jamie P., Seymour, Louise A., Ritchie, David, Gottlieb, David, Gill, Devinder and Jones, Kimberley (2012). Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta GA, United States, 8-11 December 2012. Washington, DC United States: American Society of Hematology.

Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma

2011

Journal Article

Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients

Gandhi, M. and Jones, K. (2011). Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients. Immunotherapy, 3 (12), 1441-1443. doi: 10.2217/IMT.11.135

Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients

2011

Journal Article

A novel immunodeficiency disorder characterized by genetic amplification of interleukin 25

Green, M. R., Camilleri, E., Gandhi, M. K., Peake, J. and Griffiths, L. R. (2011). A novel immunodeficiency disorder characterized by genetic amplification of interleukin 25. Genes and Immunity, 12 (8), 663-666. doi: 10.1038/gene.2011.50

A novel immunodeficiency disorder characterized by genetic amplification of interleukin 25

2011

Conference Publication

A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms

Huyen Tran, , Nourse, Jamie P., Lea, Rod, Brighton, Timothy A., Grigg, Andrew, McRae, Simon, Thurley, Daniel, Gandhi, Maher and Catalano, John (2011). A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms

2011

Journal Article

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes

Nguyen-Van, Do, Keane, Colm, Han, Erica, Jones, Kimberley, Nourse, Jamie P., Vari, Frank, Ross, Nathan, Crooks, Pauline, Ramuz, Olivier, Green, Michael, Griffith, Lyn, Trappe, Ralf, Grigg, Andrew, Mollee, Peter and Gandhi, Maher K. (2011). Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. American Journal of Blood Research, 1 (2), 146-159.

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes

2011

Journal Article

Broad-spectrum immunosuppression by classless monocytes in non-Hodgkin's lymphoma

Vari, F. and Gandhi, M.K. (2011). Broad-spectrum immunosuppression by classless monocytes in non-Hodgkin's lymphoma. Immunotherapy, 3 (6), 723-726. doi: 10.2217/IMT.11.56

Broad-spectrum immunosuppression by classless monocytes in non-Hodgkin's lymphoma

2011

Journal Article

Molecular mechanisms influencing NK cell development: implications for NK cell malignancies.

Mujaj, Sally A., Spanevello, Michelle M., Gandhi, Maher K. and Nourse, Jamie P. (2011). Molecular mechanisms influencing NK cell development: implications for NK cell malignancies.. American Journal of Blood Research, 1 (1), 34-45.

Molecular mechanisms influencing NK cell development: implications for NK cell malignancies.

2011

Journal Article

Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma

Green, Michael R., Aya-Bonilla, Carlos, Gandhi, Maher K., Lea, Rod A., Wellwood, Jeremy, Wood, Peter, Marlton, Paula and Griffiths, Lyn R. (2011). Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosomes and Cancer, 50 (5), 313-326. doi: 10.1002/gcc.20856

Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma

2011

Journal Article

Epstein-Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy

Nourse, J. P., Jones, K. and Gandhi, M. K. (2011). Epstein-Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy. American Journal of Transplantation, 11 (5), 888-895. doi: 10.1111/j.1600-6143.2011.03499.x

Epstein-Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy

2011

Conference Publication

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL

Gandhi, MK, Hertzberg, MS, Han, E, Seymour, JF, Hicks, R, Gill, DS, Keane, C, Crooks, P, Radford, K and Vari, F (2011). Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL

2011

Conference Publication

Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients

Keane, C., Shen, L., Nourse, J., Han, E., Jones, K. and Gandhi, M. (2011). Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients. 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 15-18 June 2011. Oxford, United Kingdom: Oxford University Press.

Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients

2011

Conference Publication

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

2010

Journal Article

Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders

Jones, Kimberley, Nourse, Jamie P., Morrison, Leanne, Nguyen-Van, Do, Moss, Denis J., Burrows, Scott R. and Gandhi, Maher K. (2010). Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood, 116 (13), 2245-2252. doi: 10.1182/blood-2010-03-274076

Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders

2010

Journal Article

Can a blood test monitor lymphoma?

Jones, Kimberley and Gandhi, Maher K. (2010). Can a blood test monitor lymphoma?. Leukemia and Lymphoma, 51 (6), 957-959. doi: 10.3109/10428194.2010.487623

Can a blood test monitor lymphoma?

Funding

Past funding

  • 2019 - 2020
    Indolent Lymphoma: Establishing a prognostic score fit for the modern era
    The Leukaemia Foundation of Australia Limited
    Open grant
  • 2018 - 2019
    A novel immunotherapy strategy for lymphoma using artificial microRNA gene targeting
    Metro South Hospital and Health Service
    Open grant
  • 2017 - 2019
    Pre-clinical studies of anti-LAG3 in lymphoma
    Bristol-Myers Squibb Pharmaceuticals Pty Limited
    Open grant
  • 2017
    Improving the evidence base for resource allocation in indolent lymphoma
    Gilead Australia Fellowship
    Open grant
  • 2016 - 2018
    Prognosticator for Follicular lymphoma (FL) and Mantle celly lymphoma (MCL)
    Research Donation Generic
    Open grant
  • 2016 - 2017
    Blood biomarkers in Hodgkin Lymphoma
    PA Research Foundation NHMRC Infrastructure Support
    Open grant
  • 2016
    Marshaling NK-cells in the fight against blood cancers: a novel approach
    PA Research Foundation NHMRC Near Miss Grant
    Open grant
  • 2015 - 2016
    Funding Assistance for Gandhi laboratory
    Metro South Hospital and Health Service
    Open grant
  • 2015 - 2016
    Using single-cell transcriptomics to define T-cell tolerance in EBV+ lymphoma
    PA Research Foundation
    Open grant
  • 2014 - 2018
    Leukaemia Foundation Queensland Chair in Blood Cancer Research (2014-2019)
    Leukaemia Foundation
    Open grant
  • 2014 - 2017
    Circulating Biomarkers in advanced classical Hodgkin Lymphoma
    NHMRC Project Grant
    Open grant
  • 2013 - 2014
    Monocytic myeloid derived suppressor cells and antiCD20-antibody dependent cellular cytotoxicity in diffuse large B-cell lymphoma (Cancer Council Queensland grant administered by PAH)
    Metro South Hospital and Health Service
    Open grant

Supervision

Availability

Professor Maher Gandhi is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

Contact Professor Maher Gandhi directly for media enquiries about:

  • Biomarkers
  • Immunotherapy
  • Lymphoma

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au